



Hansa Biopharma is based in Lund, Sweden with operations in other European countries and the U.S. Hansa leverages its proprietary antibody-cleaving enzyme technology platform to target pathogenic and disease causing antibodies.

Hansa's lead product, imlifidase, is an antibody-cleaving enzyme which enables kidney transplantation in highly sensitized patients. The European Commission conditionally approved Idefirix (imlifidase) for the desensitization of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor with use reserved for patients unlikely to be transplanted under available kidney allocation systems including prioritisation programmes for highly sensitised patients.